{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T17:19:02Z","timestamp":1778260742715,"version":"3.51.4"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T00:00:00Z","timestamp":1735516800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T00:00:00Z","timestamp":1735516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-83014-1","type":"journal-article","created":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T20:27:31Z","timestamp":1735590451000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Comprehensive safety evaluation of isatuximab in multiple myeloma using disproportionality analysis of FAERS and meta-analysis of randomized controlled trials"],"prefix":"10.1038","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8068-6839","authenticated-orcid":false,"given":"Muhammed","family":"Favas Karimbanathottathil","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3584-6212","authenticated-orcid":false,"given":"Beema T","family":"Yoosuf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Mamatha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4520-3293","authenticated-orcid":false,"given":"Dipika","family":"Bansal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,12,30]]},"reference":[{"issue":"5","key":"83014_CR1","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1001\/jama.2022.0003","volume":"327","author":"AJ Cowan","year":"2022","unstructured":"Cowan, A. J. et al. Diagnosis and management of multiple myeloma: A review. Jama 327(5), 464\u2013477 (2022).","journal-title":"Jama"},{"issue":"9","key":"83014_CR2","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1001\/jamaoncol.2018.2128","volume":"4","author":"AJ Cowan","year":"2018","unstructured":"Cowan, A. J. et al. Global burden of multiple myeloma: A systematic analysis for the global burden of disease study 2016. JAMA Oncol. 4(9), 1221\u20131227 (2018).","journal-title":"JAMA Oncol."},{"issue":"11","key":"83014_CR3","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1038\/leu.2017.138","volume":"31","author":"SK Kumar","year":"2017","unstructured":"Kumar, S. K. et al. Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: A multicenter IMWG study. Leukemia 31(11), 2443\u20132448 (2017).","journal-title":"Leukemia"},{"key":"83014_CR4","doi-asserted-by":"crossref","unstructured":"Abramson, H. N. Monoclonal antibodies for the treatment of multiple myeloma: An update. Int. J. Mol. Sci. 19(12) (2018).","DOI":"10.3390\/ijms19123924"},{"issue":"1","key":"83014_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2020.101143","volume":"33","author":"K Wudhikarn","year":"2020","unstructured":"Wudhikarn, K., Wills, B. & Lesokhin, A. M. Monoclonal antibodies in multiple myeloma: Current and emerging targets and mechanisms of action. Best Pract. Res. Clin. Haematol. 33(1), 101143 (2020).","journal-title":"Best Pract. Res. Clin. Haematol."},{"issue":"2","key":"83014_CR6","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/leu.2017.329","volume":"32","author":"CS Chim","year":"2018","unstructured":"Chim, C. S. et al. Management of relapsed and refractory multiple myeloma: Novel agents, antibodies, immunotherapies and beyond. Leukemia 32(2), 252\u2013262 (2018).","journal-title":"Leukemia"},{"issue":"9","key":"83014_CR7","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1007\/s40265-020-01311-1","volume":"80","author":"S Dhillon","year":"2020","unstructured":"Dhillon, S. Isatuximab: First approval. Drugs 80(9), 905\u2013912 (2020).","journal-title":"Drugs"},{"key":"83014_CR8","unstructured":"Sanofi-Aventis. SARCLISA (isatuximab): EMA summary of product characteristics. 2024 [Available from: https:\/\/www.ema.europa.eu Accessed 07 Aug 2024."},{"key":"83014_CR9","unstructured":"SARCLISA\u00ae (isatuximab-irfc) injection, for intravenous use, US prescribing information 2024 [Available from: https:\/\/www.accessdata.fda.gov Accessed 07 Aug 2024."},{"key":"83014_CR10","unstructured":"Sarclisa I.V. infusion 100mg\/Sarclisa I.V. infusion 500mg: Japanese prescribing information. 2024 [Available from: https:\/\/www.pmda.go.jp. Accessed 07 Aug 2024."},{"key":"83014_CR11","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.3389\/fimmu.2018.02134","volume":"9","author":"N van de Donk","year":"2018","unstructured":"van de Donk, N. & Usmani, S. Z. CD38 antibodies in multiple myeloma: Mechanisms of action and modes of resistance. Front. Immunol. 9, 2134 (2018).","journal-title":"Front. Immunol."},{"issue":"12","key":"83014_CR12","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1080\/14712598.2021.1841747","volume":"20","author":"PG Richardson","year":"2020","unstructured":"Richardson, P. G., Beksa\u00e7, M., \u0160pi\u010dka, I. & Mikhael, J. Isatuximab for the treatment of relapsed\/refractory multiple myeloma. Expert Opin. Biol. Ther. 20(12), 1395\u20131404 (2020).","journal-title":"Expert Opin. Biol. Ther."},{"key":"83014_CR13","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1201\/9781032629940-6","volume-title":"Role of Medical Coding in Signal Detection. Signal Analysis in Pharmacovigilance","author":"D Bansal","year":"2024","unstructured":"Bansal, D., Yoosuf, B. T. & Favas, M. K. Role of Medical Coding in Signal Detection. Signal Analysis in Pharmacovigilance 95\u2013100 (CRC Press, 2024)."},{"key":"83014_CR14","first-page":"135","volume-title":"Bayesian Methods of Signal Detection. Signal Analysis in Pharmacovigilance","author":"D Bansal","year":"2025","unstructured":"Bansal, D., Favas, M. K. & Yoosuf, B. T. Bayesian Methods of Signal Detection. Signal Analysis in Pharmacovigilance 135\u2013147 (CRC Press, 2025)."},{"issue":"6","key":"83014_CR15","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","volume":"10","author":"SJ Evans","year":"2001","unstructured":"Evans, S. J., Waller, P. C. & Davis, S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol. Drug Saf. 10(6), 483\u2013486 (2001).","journal-title":"Pharmacoepidemiol. Drug Saf."},{"issue":"10","key":"83014_CR16","first-page":"000142","volume":"10","author":"M Cumpston","year":"2019","unstructured":"Cumpston, M. et al. Updated guidance for trusted systematic reviews: A new edition of the cochrane handbook for systematic reviews of interventions. Cochr. Database Syst. Rev. 10(10), 000142 (2019).","journal-title":"Cochr. Database Syst. Rev."},{"key":"83014_CR17","doi-asserted-by":"crossref","unstructured":"Higgins, J. P., Savovi\u0107, J., Page, M. J., Elbers, R. G., & Sterne, J. A. Assessing risk of bias in a randomized trial. Cochrane Handbook for Systematic Reviews of Interventions. p. 205\u201328 (2019).","DOI":"10.1002\/9781119536604.ch8"},{"issue":"2","key":"83014_CR18","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1007\/s11121-013-0377-7","volume":"14","author":"M Borenstein","year":"2013","unstructured":"Borenstein, M. & Higgins, J. P. Meta-analysis and subgroups. Prev. Sci. 14(2), 134\u2013143 (2013).","journal-title":"Prev. Sci."},{"issue":"7414","key":"83014_CR19","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins, J. P., Thompson, S. G., Deeks, J. J. & Altman, D. G. Measuring inconsistency in meta-analyses. Bmj 327(7414), 557\u2013560 (2003).","journal-title":"Bmj"},{"issue":"20","key":"83014_CR20","doi-asserted-by":"publisher","first-page":"3443","DOI":"10.1002\/sim.2380","volume":"25","author":"RM Harbord","year":"2006","unstructured":"Harbord, R. M., Egger, M. & Sterne, J. A. A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints. Stat. Med. 25(20), 3443\u20133457 (2006).","journal-title":"Stat. Med."},{"issue":"7109","key":"83014_CR21","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger, M., Davey Smith, G., Schneider, M. & Minder, C. Bias in meta-analysis detected by a simple, graphical test. Bmj 315(7109), 629\u2013634 (1997).","journal-title":"Bmj"},{"issue":"10214","key":"83014_CR22","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1016\/S0140-6736(19)32556-5","volume":"394","author":"M Attal","year":"2019","unstructured":"Attal, M. et al. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): A randomised, multicentre, open-label, phase 3 study. Lancet 394(10214), 2096\u20132107 (2019).","journal-title":"Lancet"},{"issue":"10292","key":"83014_CR23","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1016\/S0140-6736(21)00592-4","volume":"397","author":"P Moreau","year":"2021","unstructured":"Moreau, P. et al. Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): A multicentre, open-label, randomised phase 3 trial. Lancet 397(10292), 2361\u20132371 (2021).","journal-title":"Lancet"},{"issue":"11","key":"83014_CR24","doi-asserted-by":"publisher","first-page":"e810","DOI":"10.1016\/S2352-3026(22)00263-0","volume":"9","author":"H Goldschmidt","year":"2022","unstructured":"Goldschmidt, H. et al. Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): Part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial. Lancet Haematol. 9(11), e810\u2013e821 (2022).","journal-title":"Lancet Haematol."},{"issue":"2","key":"83014_CR25","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s12185-024-03800-5","volume":"120","author":"N Tagami","year":"2024","unstructured":"Tagami, N. et al. Isatuximab with pomalidomide-dexamethasone in relapsed\/refractory multiple myeloma: Post-marketing surveillance in Japan. Int. J. Hematol. 120(2), 217\u2013228 (2024).","journal-title":"Int. J. Hematol."},{"issue":"3","key":"83014_CR26","volume":"14","author":"PO Idogun","year":"2022","unstructured":"Idogun, P. O. & Kayali, Z. Hemorrhagic chemosis associated with isatuximab use in an elderly lady with multiple myeloma. Cureus 14(3), e22764 (2022).","journal-title":"Cureus"},{"key":"83014_CR27","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1182\/blood-2023-179925","volume":"142","author":"C Rodriguez","year":"2023","unstructured":"Rodriguez, C. et al. The impact of isatuximab regimens on hypogammaglobulinemia occurrence, recovery, and associated infections in patients with relapsed\/refractory multiple myeloma. Blood 142, 1980 (2023).","journal-title":"Blood"},{"issue":"5","key":"83014_CR28","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1007\/s11523-021-00827-0","volume":"16","author":"JE Frampton","year":"2021","unstructured":"Frampton, J. E. Isatuximab: A review of its use in multiple myeloma. Target Oncol. 16(5), 675\u2013686 (2021).","journal-title":"Target Oncol."},{"key":"83014_CR29","doi-asserted-by":"publisher","first-page":"153303382211065","DOI":"10.1177\/15330338221106563","volume":"21","author":"F Shen","year":"2022","unstructured":"Shen, F. & Shen, W. Isatuximab in the treatment of multiple myeloma: A review and comparison with daratumumab. Technol. Cancer Res. Treat. 21, 15330338221106564 (2022).","journal-title":"Technol. Cancer Res. Treat."},{"issue":"25","key":"83014_CR30","doi-asserted-by":"publisher","first-page":"3294","DOI":"10.1182\/blood-2016-09-740787","volume":"129","author":"T Martin","year":"2017","unstructured":"Martin, T. et al. A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed\/refractory multiple myeloma. Blood 129(25), 3294\u20133303 (2017).","journal-title":"Blood"},{"issue":"1","key":"83014_CR31","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1002\/cpt.2920","volume":"114","author":"S Xia","year":"2023","unstructured":"Xia, S. et al. Tumor lysis syndrome associated with monoclonal antibodies in patients with multiple myeloma: A pharmacovigilance study based on the FAERS database. Clin. Pharmacol. Ther. 114(1), 211\u2013219 (2023).","journal-title":"Clin. Pharmacol. Ther."},{"issue":"6","key":"83014_CR32","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1007\/s11096-023-01608-7","volume":"45","author":"DC Moore","year":"2023","unstructured":"Moore, D. C., Elmes, J. B., Arnall, J. R., Strassels, S. A. & Patel, J. N. Hepatitis B reactivation in patients with multiple myeloma treated with anti-CD38 monoclonal antibody-based therapies: A pharmacovigilance analysis. Int. J. Clin. Pharm. 45(6), 1492\u20131495 (2023).","journal-title":"Int. J. Clin. Pharm."},{"key":"83014_CR33","doi-asserted-by":"crossref","unstructured":"Kt, M. F., Semwal, M., Yoosuf, B. T., Lad, D., & Bansal, D. Venetoclax adverse event monitoring: A safety meta-analysis of randomized controlled trials and a retrospective evaluation of the FAERS. Ann. Hematol. pp 1\u201313 (2024).","DOI":"10.1007\/s00277-024-05676-1"},{"key":"83014_CR34","doi-asserted-by":"crossref","unstructured":"Yoosuf, B. T., Favas, K. T. M., Dutta, P., & Bansal. D. Comprehensive safety profile of dipeptidyl peptidase-4 inhibitors: A post-marketing study based on FAERS database using signal detection algorithms. Expert Opin. Drug Saf. pp 1\u201313. (2024).","DOI":"10.1080\/14740338.2024.2343015"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-83014-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-83014-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-83014-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T15:33:45Z","timestamp":1735659225000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-83014-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,30]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["83014"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-83014-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,30]]},"assertion":[{"value":"24 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"31859"}}